Project Details
Description
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (CTN1302)
| Status | Finished |
|---|---|
| Effective start/end date | 8/17/15 → 2/28/19 |
Funding
- NATIONAL MARROW DONOR PROGRAM
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.